AVEO Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 02 2019 - 7:05AM
Business Wire
AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey,
president and chief executive officer, will present at the 37th
Annual J.P. Morgan Healthcare Conference in San Francisco on
Wednesday, January 9, 2019 at 4:00 p.m. Pacific Time.
A live webcast of the presentation can be accessed by visiting
the investors section of the Company’s website at
www.aveooncology.com. A replay of the webcast will be archived for
30 days following the presentation date.
About AVEO
AVEO Pharmaceuticals, Inc. (the “Company” or “AVEO”) is a
biopharmaceutical company dedicated to advancing a broad portfolio
of targeted medicines for oncology and other areas of unmet medical
need. The Company’s strategy is to retain North American rights to
its oncology portfolio while securing partners in development and
commercialization outside of North America. The Company is seeking
to develop and commercialize its lead candidate tivozanib in North
America as a treatment for advanced or metastatic renal cell
carcinoma (“RCC”). The Company has outlicensed tivozanib (FOTIVDA®)
for oncological indications in Europe and other territories outside
of North America. Tivozanib is approved in the European Union, as
well as Norway and Iceland, for the first-line treatment of adult
patients with RCC and for adult patients who are vascular
endothelial growth factor receptor and mTOR pathway inhibitor-naïve
following disease progression after one prior treatment with
cytokine therapy for RCC. The Company has entered into partnerships
for the development and commercialization of AV-203 (CAN017) and
ficlatuzumab, both clinical stage assets in oncology. The Company
is currently seeking a partner to develop the AV-353 platform, a
preclinical asset, worldwide for the potential treatment of
pulmonary arterial hypertension and oncology. In addition, a new
formulation of tivozanib is being explored in ocular conditions.
The Company has recently regained the rights to its AV-380 program
for the potential treatment of cachexia and is considering a
variety of options to advance the program’s development.
For more information, please visit the Company’s website at
www.aveooncology.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO
that involve substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Actual results or events
could differ materially due to a number of important factors,
including risks discussed in the section titled “Risk Factors” in
AVEO’s most recent Annual Report on Form 10-K, its quarterly
reports on Form 10-Q and its other filings with the SEC. The
forward-looking statements in this press release represent AVEO’s
views as of the date of this press release. AVEO anticipates that
subsequent events and developments may cause its views to change.
While AVEO may elect to update these forward-looking statements at
some point in the future, it specifically disclaims any obligation
to do so. You should, therefore, not rely on these forward-looking
statements as representing AVEO’s views as of any date other than
the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190102005151/en/
AVEO Contact:David Pitts, Argot Partners(212)
600-1902aveo@argotpartners.com
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From May 2024 to Jun 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Jun 2023 to Jun 2024